500
These outcomes (4) were significantly different between endocrine therapy +/- RT in the phase III RCT (SPCG, Widmark, Lancet Onc 2009) in locally advanced prostate cancer patients
***DAILY DOUBLE
What are 10 yr overall mortality (40% vs 30%), cancer specific mortality (24% vs 12%), and PSA recurrence (75% vs 25%)?